Welcome to our dedicated page for Beam Therapeutics news (Ticker: BEAM), a resource for investors and traders seeking the latest updates and insights on Beam Therapeutics stock.
Beam Therapeutics Inc. (Nasdaq: BEAM) generates frequent news as a biotechnology company developing precision genetic medicines through base editing. News about BEAM stock often centers on clinical data readouts, regulatory designations and strategic updates across its hematology and liver-targeted genetic disease franchises.
Investors following BEAM news can expect detailed updates on risto-cel (formerly BEAM-101), an investigational ex vivo base editing cell therapy for sickle cell disease with severe vaso-occlusive crises. The company regularly reports safety and efficacy data from the BEACON Phase 1/2 trial, including measures such as fetal hemoglobin induction, reductions in sickle hemoglobin, engraftment times and markers of hemolysis, as well as designations like RMAT and orphan drug status from the U.S. Food and Drug Administration.
Another major source of headlines is BEAM-302, Beam’s liver-targeting program for alpha-1 antitrypsin deficiency (AATD). Company press releases describe Phase 1/2 trial progress, dose exploration, evidence of in vivo genetic correction of a disease-causing mutation, restoration of functional alpha-1 antitrypsin and regulatory interactions, including RMAT designation, orphan drug designation and participation in the FDA’s CDRP program.
Additional BEAM news items highlight developments in BEAM-301 for glycogen storage disease type Ia, the ESCAPE platform and BEAM-103 antibody, targeted lipid nanoparticle delivery research, financial results, cash runway commentary and participation in scientific and investor conferences. Coverage may also reference Beam’s equity stake in Orbital Therapeutics and the impact of Orbital’s acquisition by Bristol Myers Squibb, as disclosed by the company.
For readers tracking BEAM, this news feed provides ongoing insight into Beam’s clinical milestones, regulatory pathways, platform evolution and corporate transactions that shape the outlook for its precision genetic medicines pipeline.
Beam Therapeutics (Nasdaq: BEAM) has appointed Kate Walsh, President and CEO of Boston Medical Center, to its board of directors. Walsh brings extensive experience in leading healthcare organizations, which is expected to enhance Beam's mission of developing precision genetic medicines through base editing. The company anticipates 2021 to be a pivotal year, with plans for filing its first Investigational New Drug application. Both Walsh and Beam’s leadership express optimism about the potential impact of its innovative treatments on patients with serious diseases.
Beam Therapeutics (Nasdaq: BEAM) will have CEO John Evans presenting at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 11:40 a.m. ET. Investors can access a live webcast on the company’s website, which will also be archived for 60 days. Beam Therapeutics specializes in precision genetic medicines using base editing technology, allowing precise genomic modifications without DNA breaks. Their innovative approach aims to deliver effective therapeutic solutions for serious diseases.
Beam Therapeutics (Nasdaq: BEAM) announced significant findings regarding its base editing technology during the 62nd American Society of Hematology Annual Meeting. Data from the BEAM-101 program showed no off-target editing, supporting a future Investigational New Drug application in H2 2021. The Makassar base editor demonstrated a 50% conversion of the sickle allele to a non-disease variant, with evidence of sustained editing after 16 weeks. These advancements may lead to effective treatments for sickle cell disease, affecting nearly 100,000 Americans.
Summary not available.
Beam Therapeutics (Nasdaq: BEAM) presented promising preclinical data at the AASLD The Liver Meeting, focusing on a novel base-editing strategy targeting two prevalent mutations in Glycogen Storage Disease Type Ia (GSDIa). The engineered adenine base editors (ABE) achieved significant mutation correction levels, exceeding the therapeutic threshold necessary for restoring glucose homeostasis. With no approved pharmacological treatments currently available for GSDIa, these findings suggest a potential breakthrough for effective, life-long therapies for patients suffering from this disorder.
Beam Therapeutics (Nasdaq: BEAM) has named BEAM-201 as a development candidate for treating T-cell acute lymphoblastic leukemia (T-ALL), showcasing significant advances in their base editing platform. The company reported a successful follow-on offering, raising approximately $135.1 million in October 2020. In Q3 2020, Beam's cash position reached $202.2 million, but the company incurred a net loss of $34.5 million or $0.69 per share. Upcoming data presentations include advancements in treating glycogen storage disease and sickle cell disease.
Beam Therapeutics has named BEAM-201 as a development candidate for T-cell acute lymphoblastic leukemia (T-ALL). This innovative allogeneic CAR-T therapy features simultaneous edits to four genes, achieving 96-99% on-target editing. Preclinical results show strong dose-dependent tumor control in mouse models. BEAM-201 is produced in a GMP-compliant process, utilizing T cells from healthy donors, making it an 'off-the-shelf' treatment option. The therapy addresses a severe condition, with a five-year survival rate of under 25%.
Beam Therapeutics (Nasdaq: BEAM) announced the participation of CEO John Evans in a fireside chat at the Chardan Virtual 4th Annual Genetic Medicines Conference on October 5, 2020, at 8:00 a.m. ET. The event will be accessible via a live webcast on the investor section of the company’s website, www.beamtx.com, and will be archived for 60 days post-event.
Beam Therapeutics specializes in precision genetic medicines utilizing base editing technologies to develop targeted genomic therapies, positioning itself as a leader in the biotech sector.
Beam Therapeutics Inc. (Nasdaq: BEAM) has announced the pricing of its public offering, aiming to sell 5,000,000 shares at $23.50 each. The company expects gross proceeds of approximately $117.5 million, excluding underwriter options for an additional 750,000 shares. This offering is set to close on October 5, 2020, pending customary conditions. J.P. Morgan, Jefferies, and Barclays are the joint book-running managers, with Wedbush PacGrow as the lead manager. The registration statement for the shares was effective as of September 30, 2020.
Beam Therapeutics (Nasdaq: BEAM) announced a proposed public offering of 4,500,000 shares of its common stock, with an option for underwriters to purchase an additional 675,000 shares. The offering will be managed by J.P. Morgan, Jefferies, and Barclays, with Wedbush PacGrow as the lead manager. A registration statement has been filed with the SEC, but it has not yet been declared effective. Investors are advised to review the prospectus for detailed information before investing. The company focuses on precision genetic medicines through base-editing technology.
FAQ
What is the current stock price of Beam Therapeutics (BEAM)?
What is the market cap of Beam Therapeutics (BEAM)?
